Eli Lilly has new data that could help expand Cyramza’s lung cancer footprint. But if it does win approval to treat EGFR-mutated tumors, it’ll face a tough field of competitors. More: Lilly's Cyramza scores in targeted lung cancer—but major competition
read moreSome Big Pharma CEOs got eye-popping pay raises last year, even if their companies blundered. Sanofi chief Olivier Brandicourt wasn’t one of them. He took a pay cut, in fact, as U.S. sales of the company’s flagship diabetes products continued
read moreAdults with lymphoma will not be able to access Novartis’ CAR-T therapy Kymriah on the NHS in Scotland after cost-regulators rejected funding for the treatment in this setting. More: SMC says ‘no’ to Novartis’ Kymriah for adults with lymphoma Source:
read moreTakeda’s Entyvio has beaten AbbVie’s Humira on achieving clinical remission in patients with ulcerative colitis, in the first trial to directly compare the efficacy and safety of two commonly used biologics for the disease. More: Takeda’s Entyvio bests AbbVie’s Humira
read moreUS regulators have accepted for review Allergan’s application to market ubrogepant for the acute treatment of migraine. More: Allergan files anti-CGRP migraine drug in the US Source: News
read moreHealth Minister Nicola Blackwood has announced up to £56 million funding for research into the biggest challenges facing public health – climate change, air pollution, antimicrobial resistance and global pandemics. More: Gov’t offers £56m for research into public health challenges
read more© 1994 - 2026 B.M. Pharmaceuticals